Lyell Immunopharma (NASDAQ:LYEL) Stock Rating Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Lyell Immunopharma (NASDAQ:LYEL) from a sell rating to a hold rating in a research report sent to investors on Sunday,Wall Street Zen reports.

A number of other equities analysts also recently commented on LYEL. Stifel Nicolaus started coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They set a “buy” rating and a $36.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. B. Riley Financial assumed coverage on Lyell Immunopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price objective for the company. Finally, Royal Bank Of Canada set a $34.00 price objective on Lyell Immunopharma in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.86.

Lyell Immunopharma Price Performance

Shares of NASDAQ LYEL opened at $9.39 on Friday. The stock’s 50-day moving average is $11.47 and its two-hundred day moving average is $14.62. Lyell Immunopharma has a 1-year low of $7.20 and a 1-year high of $45.00. The company has a market cap of $230.06 million, a price-to-earnings ratio of -0.73 and a beta of -0.03.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Equities research analysts anticipate that Lyell Immunopharma will post -7.16 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Several institutional investors have recently modified their holdings of LYEL. Opaleye Management Inc. grew its position in shares of Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after buying an additional 264,928 shares during the last quarter. venBio Partners LLC acquired a new stake in Lyell Immunopharma during the 2nd quarter worth $4,744,643. Renaissance Technologies LLC raised its stake in Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after acquiring an additional 76,921 shares in the last quarter. Velan Capital Investment Management LP lifted its position in Lyell Immunopharma by 2.9% in the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Lyell Immunopharma in the first quarter valued at $959,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.